Dataset from A Randomized, Open-Label, Neoadjuvant Prostate Cancer Trial of Abiraterone Acetate Plus LHRHa Versus LHRHa Alone

The goal of this clinical research study is to find out how treatment with abiraterone acetate in combination with prednisone and a Luteinizing Hormone-Releasing Hormone (LHRH) analogue changes the tumor in comparison to treatment with an LHRH analogue alone. Objectives: Primary Objective: To assess the difference in pathologic stage < pT2 between Group A and Group B. Secondary Objective: - To assess and compare the changes in levels of androgens (pre, during, and post treatment) in the serum, primary tumor microenvironment and bone marrow between Group A and Group B. - To assess changes in biomarkers related to androgen signaling and other cancer-related pathways between Group A and Group B. - To assess the difference in rate of positive surgical margins between Group A and Group B. - To assess the safety profile of abiraterone acetate and low dose prednisone in a preoperative setting.